Related Experiment Video

Updated: Sep 29, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
11:17

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Published on: January 7, 2016

Final height after growth hormone therapy in peripubertal boys with a subnormal integrated concentration of growth

Z Zadik1, U Mira, H Landau

  • 1Pediatric Endocrine Unit, Kaplan Hospital, Rehovot, Israel.

Hormone Research
|January 1, 1992
PubMed

Insights

Growth hormone (GH) therapy significantly improved final height in peripubertal boys with idiopathic short stature, reaching predicted heights. The treatment

Area of Science:

  • Pediatric Endocrinology
  • Growth and Development
  • Hormone Therapy

Background:

  • Idiopathic short stature (ISS) affects peripubertal boys, impacting final height.
  • Subnormal growth hormone (GH) levels are a key indicator in ISS diagnosis.
  • Assessing the efficacy of GH therapy is crucial for optimizing treatment outcomes.

Purpose of the Study:

  • To evaluate the effect of recombinant human growth hormone (rhGH) therapy on final height in peripubertal boys with ISS.
  • To compare the final height of treated boys with their target and predicted heights.
  • To analyze growth velocity changes during rhGH treatment.

Main Methods:

  • A cohort of 28 peripubertal boys with ISS and subnormal GH levels were studied.
  • Eleven boys received rhGH therapy (0.75 unit/kg/week) for 2 years, followed by daily injections until final height.
  • Seventeen boys served as an untreated control group, monitored until growth cessation.

Main Results:

  • GH-treated boys achieved final heights closer to their target and predicted heights compared to untreated controls.
  • Significant increases in height velocity were observed during the first year of GH therapy (p < 0.001).
  • Untreated boys attained final heights significantly below their target and predicted heights.

Conclusions:

  • Recombinant human growth hormone therapy is effective in improving final height for peripubertal boys with idiopathic short stature.
  • Early intervention with GH therapy leads to accelerated growth velocity, particularly in the initial treatment year.
  • The benefits of GH therapy on final height should be considered alongside treatment costs.

More Related Videos

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Related Concept Videos

Polygenic Traits01:35

Polygenic Traits

When more than one gene is responsible for a given phenotype, the trait is considered polygenic. Human height is a polygenic trait. Studies have uncovered hundreds of loci that influence height, and there are believed to be many more. Due to the high number of genes involved, as well as environmental and nutritional factors, height varies significantly within a given population. The distribution of height forms a bell-shaped curve, with relatively few individuals in the population at the...
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Cellular Adaptation III: Hyperplasia01:26

Cellular Adaptation III: Hyperplasia

Hyperplasia is an increase in the number of cells in a tissue or organ due to enhanced cell division. It is an adaptive, controlled response to stimuli such as injury, hormones, or stress, involving mitosis to produce genetically identical cells and support tissue repair and regeneration.Tissue CapacityCertain tissues, including the epidermis, intestinal epithelium, bone marrow, and fibroblasts, have a high potential for hyperplasia. Others, such as bone, cartilage, and smooth muscle, show...